<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771039</url>
  </required_header>
  <id_info>
    <org_study_id>HRIPH</org_study_id>
    <nct_id>NCT04771039</nct_id>
  </id_info>
  <brief_title>Ocular Manifestations of Inflammatory Bowel Disease</brief_title>
  <official_title>Ocular Manifestations of Chronic Inflammatory Bowel Disease (IBD): Retrospective Study in the Hepato-gastroenterology Department of the Nancy CHRU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ocular damage is found in the 3rd rank of extra intestinal manifestations (MEI) Potentially&#xD;
      serious functional complications (see uveitis and risk of blindness) requiring rapid&#xD;
      management Rare uveitis in the literature (0.5% -3%), study on a large sample to assess their&#xD;
      prevalence in patients with IBD at the Nancy CHRU and describe all the ocular manifestations&#xD;
      that can be found.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Actual">December 12, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>frequency</measure>
    <time_frame>baseline</time_frame>
    <description>frequency of ocular manifestations in inflammatory bowel disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number</measure>
    <time_frame>baseline</time_frame>
    <description>Number of uveitis, scleritis and episcleritis; prevalence calculation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">87</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>patients with chronic inflammatory bowel disease who consulted in ophthalmology</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>reason for consultation</intervention_name>
    <description>search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD</description>
    <arm_group_label>patients with chronic inflammatory bowel disease who consulted in ophthalmology</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients followed at Nancy University Hospital for IBD and having consulted in the&#xD;
        ophthalmology department&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients followed at Nancy University Hospital for IBD and having consulted in&#xD;
             the ophthalmology department&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor patients&#xD;
&#xD;
          -  patients without IBD&#xD;
&#xD;
          -  patients for whom there is no ophthalmology consultation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

